ESHAP
ESHAP is an acronym for relatively intensive chemotherapy regimen that is used for salvage therapy in relapsed or refractory lymphomas and Hodgkin lymphoma.
≈ 2 min read
ESHAP. encyclopegia.org, snapshot enwiki-001294953504. /a/eshap
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
ESHAP is an acronym for relatively intensive chemotherapy regimen that is used for salvage therapy in relapsed or refractory lymphomas and Hodgkin lymphoma. In combination with monoclonal antibody Rituximab it is called R-ESHAP or ESHAP-R.[1]
R-ESHAP consists of:
- Rituximab, an anti-CD20-directed monoclonal antibody that kills both normal and malignant B-lymphocytes
- Etoposide, an epipodophyllotoxin topoisomerase inhibitor
- Solu-Medrol - Methylprednisolone, which is a glucocorticoid that can lyse lymphocytes
- High-dose Ara-C - cytarabine
- Platinol - Cisplatin, a platinum-based antineoplastic agent, also an alkylating antineoplastic agent.
Dosing regimen
edit edit source| Drug | Dose | Mode | Days |
|---|---|---|---|
| Rituximab | 375 mg/m2 | IV infusion | Day 0 |
| Etoposide | 40 mg/m2 | IV infusion over 1 hr | Days 1-4 |
| Solu-Medrol - Methylprednisolone | 500 mg | IV bolus over 15 min | Days 1-5 |
| High-dose Ara-C — cytarabine | 2000 mg/m2 | IV infusion over 2 hrs | Day 5 |
| Platinol (cisplatin) | 25 mg/m2 | IV continuous infusion over 24 hrs | Days 1-4 |
References
edit edit source- ^ ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. Wikipedia revision 1294953504, retrieved 2026-11-19
Text derived from https://en.wikipedia.org/w/index.php?oldid=1294953504 under CC BY-SA 4.0; modifications have been made.